New Delhi: Healthcare tech firm Indegene on Thursday said it has tied up with Microsoft to empower global life sciences firms to adopt Generative AI (GenAI) services, which will drive faster innovation at scale.
The companies have committed resources to develop medical and technology tools to co-innovate generic AI services and workflows across commercial, medical, regulatory and clinical functions.
“GenAI presents a once-in-a-decade opportunity for life sciences companies to modernize business processes and reimagine the effectiveness and efficiency of their operations across the entire value chain.
“Using GenAI, we are working closely with many of our customers to solve specific business problems, with approximately 50 real-world use cases already in advanced pilot stage,” said Tarun Mathur, Inengine CTO. "
Alok Lal, Chief Operating Officer, Microsoft India and South Asia, said that Generative AI is profoundly shaping every industry, including life sciences, by providing unprecedented opportunities for healthcare technology advancements.
“By seamlessly integrating Inengine’s domain knowledge with Microsoft Azure OpenAI Service and Microsoft Copilot, we stand at the forefront of advancing generic AI in the life sciences sector,” he said.
This collaborative effort empowers life sciences companies to fully utilize the capabilities of AI, driving innovation and scalability within the industry, Lall said.
The companies have committed resources to develop medical and technology tools to co-innovate generic AI services and workflows across commercial, medical, regulatory and clinical functions.
“GenAI presents a once-in-a-decade opportunity for life sciences companies to modernize business processes and reimagine the effectiveness and efficiency of their operations across the entire value chain.
“Using GenAI, we are working closely with many of our customers to solve specific business problems, with approximately 50 real-world use cases already in advanced pilot stage,” said Tarun Mathur, Inengine CTO. "
Alok Lal, Chief Operating Officer, Microsoft India and South Asia, said that Generative AI is profoundly shaping every industry, including life sciences, by providing unprecedented opportunities for healthcare technology advancements.
“By seamlessly integrating Inengine’s domain knowledge with Microsoft Azure OpenAI Service and Microsoft Copilot, we stand at the forefront of advancing generic AI in the life sciences sector,” he said.
This collaborative effort empowers life sciences companies to fully utilize the capabilities of AI, driving innovation and scalability within the industry, Lall said.
